Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMOTE: Reduced-dose prasugrel monotherapy after PCI
2024-520351-24-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of prasugrel in acute coronary syndrome (ACS), Chronic Coronary Syndrome (CCS), coronary arteriosclerosis and 4 more, sponsored by Amsterdam University Medical Center. Primary endpoint: Net Adverse Clinical Events (NACE). Planned start Jul 2025; status: authorised.
02
Drugs
prasugrel
03
Conditions
acute coronary syndrome (ACS)Chronic Coronary Syndrome (CCS)coronary arteriosclerosismyocardial infarction (MI)ischemic stroke
Beyond the preview
Go deeper on 2024-520351-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520351-24-00.